Will a Trastuzumab Biosimilar Work in Early HER2+ Breast Cancer?

The trastuzumab biosimilar ABP 980 showed noninferiority to trastuzumab in a large trial of patients with early HER2-positive breast cancer.

Source: CancerNetwork - June 20, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news